These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 20186933)
21. [Diagnostics and drug therapy of multiple sclerosis]. Suomen Neurologinen Yhdistys ry Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889 [No Abstract] [Full Text] [Related]
22. Treatment of children and adolescents with multiple sclerosis. Banwell B Expert Rev Neurother; 2005 May; 5(3):391-401. PubMed ID: 15938672 [TBL] [Abstract][Full Text] [Related]
23. Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis. Beiske AG; Myhr KM J Neurol; 2006 Mar; 253(3):377-8. PubMed ID: 16502214 [No Abstract] [Full Text] [Related]
24. Interferon beta-1a treatment and African Americans. Cantor FK Arch Neurol; 2006 Apr; 63(4):627-8; author reply 628. PubMed ID: 16606785 [No Abstract] [Full Text] [Related]
28. Shortcomings in pharmacy benefit forecasting--interferon beta products. Rich SJ; Meyer C J Manag Care Pharm; 2003; 9(4):373; author reply 374. PubMed ID: 14613461 [No Abstract] [Full Text] [Related]
29. Anaphylactoid reaction to methyl prednisolone developing after starting treatment with interferon beta-1b. Clear D J Neurol Neurosurg Psychiatry; 1999 May; 66(5):690. PubMed ID: 10348645 [No Abstract] [Full Text] [Related]
30. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis. Petkau J; White R Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643 [No Abstract] [Full Text] [Related]
31. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis]. Seres E; Vécsei L Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710 [TBL] [Abstract][Full Text] [Related]
32. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology; 1994 Aug; 44(8):1537-40. PubMed ID: 8058168 [No Abstract] [Full Text] [Related]
37. [Changes in quality of life in patients with remitted multiple sclerosis during the specific treatment with disease-modifying drugs: a comparative study of populations of Moscow and Novosibirsk]. Popova EV; Riabukhina OV; Vorob'eva OV; Malkova NA; Boĭko AN Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):67-70. PubMed ID: 21322129 [No Abstract] [Full Text] [Related]
38. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L; Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722 [TBL] [Abstract][Full Text] [Related]
39. New treatments and azathioprine in multiple sclerosis. Kolar OJ Lancet; 1997 Oct; 350(9083):1033. PubMed ID: 9329539 [No Abstract] [Full Text] [Related]
40. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Hernandez L; Guo S; Kinter E; Fay M J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]